Studies evaluating mTOR inhibition through Everolimus (NCT01880749, NCT01419639), Everolimus in combination with Octreotide (NCT02333565), and Vistusertib (AZD2014) (NCT03071874, NCT02831257) have demonstrated promising results in terms of tumor volume reduction and progression-free survival[72,73]. The gene discussed is MTOR; the disease is neoplasm.